**Author details**

Irina Panovska-Stavridis University Clinic of Hematology, Skopje, Republic of North Macedonia

\*Address all correspondence to: dr\_irina@yahoo.com

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**235**

*Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated…*

a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008; 111(5):2776-2784. doi: 10.1182/

[9] Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification

2016;374(23):2209-2221. doi: 10.1056/

[10] Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23(1):203-206. doi:

and prognosis in acute myeloid leukemia. N Engl J Med.

blood-2007-08-109090

NEJMoa1516192

10.1038/leu.2008.173.

bjh.16355

[11] Loke J, Malladi R, Moss P,

Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129-146. doi:10.1111/

[12] Evseeva I, Foeken L, Madrigal A. The Role of Unrelated Donor Registries in HSCT. In: Carreras E, Dufour C, Mohty M, et al., editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 3. doi: 10.1007/978-3-030-02278-5\_3

[13] Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient

[14] Lown RN, Philippe J, Navarro W, et al. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group

HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583. doi:10.1182/

blood-2007-06-097386

*DOI: http://dx.doi.org/10.5772/intechopen.94830*

[1] Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. doi:10.3322/

[3] De Kouchkovsky I, Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016 Jul 1;6(7):e441. doi: 10.1038/

[4] Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87. doi:10.1016/j.

[5] Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition, Volume 2

[6] Neuendorff NR, Burmeister T, Dörken B, Westermann J. BCR-ABLpositive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Ann Hematol. 2016;95(8):1211-1221. doi:10.1007/

[7] Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. doi:10.1182/

[8] Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in

NEJMra1406184.

**References**

caac.21551

bcj.2016.50.

blre.2019.04.005

s00277-016-2721-z

blood-2016-08-733196

*Molecular Monitoring in Acute Myeloid Leukemia Patients Undergoing Matched Unrelated… DOI: http://dx.doi.org/10.5772/intechopen.94830*
